Amerigroup STAR+PLUS MMP (Medicare-Medicaid Plan) is a health plan that contracts with both Medicare and Texas Medicaid to provide benefits of both programs to enrollees.

Addition to Part B drug list of injectables/infusibles: Praluent, Repatha and Sylvant

Amerigroup STAR+PLUS MMP (Medicare-Medicaid Plan) is adding the following three new injectable drugs to the 2016 list of Part B Injectables/Infusibles. As of January 1, 2016, providers must call for prior authorization of these drugs:

1. Praluent (alirocumab): used to reduce serum low-density lipoprotein cholesterol (LDL-C)
   a. Unlisted, no J code established for the precertification list at this time
2. Repatha (evolocumab): used to reduce serum low-density lipoprotein cholesterol (LDL-C)
   a. Unlisted, no J code established for the precertification list at this time
3. Sylvant (siltuxumab): for treatment of Multicentric Castleman’s disease (MCD)
   a. Code C9455

Please note that Praluent and Repatha are currently billed under the not otherwise classified (NOC) J codes J3490 and J3590, and Sylvant is using code C9455. Since these codes include all drugs NOC, the plan’s denial will be for the drug and not the HCPCS. That is, a denial will be issued if there is no authorization on file and precertification for the drug was not obtained for the date(s) of service on the claims submitted. Payment would be denied.

Should you need further assistance please call Provider Services at 1-855-878-1785.